
    
      Enrollment closed after 3 patients were enrolled. This voluntary action was prompted by the
      announcement that the Southwest Oncology Group (SWOG) S0205 trial (NCT00075686), A Phase III
      Randomized Open Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus
      Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer, did not meet its
      primary endpoint of improving overall survival).
    
  